The management of severe eosinophilic asthma has been a contentious topic in the medical community for years. However, a study published in The Lancet recently offers a new perspective. The research indicates that for patients with severe eosinophilic asthma who are controlled on bevacizumab, tapering of inhaled corticosteroids (ICS) is feasible and does not lead to worse asthma control.
Table of Contents
Study Overview
The study involved a phase 4 trial with adults who had received at least three consecutive doses of benralizumab. The participants were randomly assigned to either taper their high-dose ICS to a medium-dose, low-dose, and as-needed dose or to continue therapy for 32 weeks. The trial included a reduction period and a maintenance period, with the primary endpoint being the proportion of patients who decreased their ICS-formoterol maintenance dose.
Findings of the Study
The findings were quite significant. An impressive 92% of the patients were able to successfully reduce their high-dose ICS, with more than 60% reducing to an anti-inflammatory reliever only, without any change in asthma control. The reductions were maintained until week 48 in 96% of the patients in the tapering group, and 91% had zero exacerbations during tapering. It’s also noteworthy that the mean change in total daily ICS dose was significantly lower in the reduction group compared to the reference group.
Adverse Events and Safety Considerations
Regarding safety, the rates of adverse events were similar between the reduction and reference groups, with no reported deaths. This suggests that the tapering of ICS is a safe approach for patients with severe eosinophilic asthma controlled on benralizumab. Clinical remission was also observed in the reduction group.
Implications and Future Directions
The results of this study could have far-reaching implications for the management of severe eosinophilic asthma. If further research corroborates these findings, it could potentially change the way we approach treatment for these patients. Tapering off high-dose ICS could reduce the risk of side effects associated with long-term steroid use while maintaining effective asthma control.
Contributors and Funding
It’s important to note that the study was funded by AstraZeneca, the manufacturer of benralizumab. Several authors also disclosed ties to pharmaceutical companies. While this does not invalidate the findings, it’s an important factor to consider when interpreting the results.
Conclusion
In conclusion, this study provides promising evidence that tapering of inhaled corticosteroids is feasible and safe for patients with severe eosinophilic asthma controlled on bevacizumab. However, more research is needed to confirm these findings and to fully understand the long-term implications of this treatment approach.
